Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Neurogenomics Market Size, Value And Growth Trends Through 2030
The neurogenomics sector has experienced significant expansion lately, with projections indicating a climb from $1.5 billion in 2025 to $1.72 billion in 2026, reflecting a compound annual growth rate of 14.7%. This historical growth trajectory has been propelled by innovations in genomic sequencing, increased financial support for neuroscience studies, a rising incidence of neurological conditions, enhanced accessibility of bioinformatics resources, and strengthened academic partnerships.
The neurogenomics sector is poised for substantial expansion in the coming years, with projections indicating a market valuation of $2.98 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.7%. This projected surge is fueled by several key factors, including the growing incorporation of genomic insights into clinical neurology practices, escalating investments dedicated to precision neurology initiatives, the broader adoption of cloud-based solutions for genomic data analysis, a heightened demand for tailored neurological treatments, and a strengthened emphasis on research that bridges basic science with clinical application in neuroscience. During this anticipated growth period, several significant trends are expected to shape the market landscape. These include a wider embrace of next-generation sequencing technologies within neuroscience research, increased utilization of integrated multi-omics data, a growing need for gene expression analysis specifically within the field of neurology, the continuous expansion of personalized research approaches concerning neurological conditions, and a reinforced commitment to studies of brain disorders that leverage data-driven methodologies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25845&type=smp
Neurogenomics Market Demand Drivers Creating New Revenue Opportunities
The expansion of the neurogenomics sector is anticipated to be significantly boosted by the increasing incidence of neurological conditions, which encompass a range of medical issues affecting the brain, spinal cord, or nerves and manifesting as symptoms like muscle weakness, seizures, pain, or cognitive challenges. Factors including suboptimal dietary habits, insufficient physical activity, persistent stress, and heightened exposure to environmental pollutants are commonly cited as contributors to the growing rates of these disorders. Neurogenomics offers profound insights into the genetic underpinnings of brain function and malfunction, thereby facilitating the pinpointing of underlying causes, refining diagnostic capabilities, and developing more effective, specialized therapies for neurological ailments. As an illustration, the Alzheimer’s Association reported in March 2023 that around 6.7 million individuals in the United States aged 65 and above were affected by Alzheimer’s dementia, with projections indicating this figure could escalate to 13.8 million by the year 2060, underscoring how the escalating frequency of neurological disorders is fueling the neurogenomics market’s growth.
Neurogenomics Market Segmentation Trends And Revenue Drivers
The neurogenomics market covered in this report is segmented –
1) By Offering: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Software And Services
2) By Application: Variant Discovery, Research Applications, Target Identification, Transcription Factor Binding Analysis, Functional Studies, Clinical Applications
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Diagnostic Laboratories
Subsegments:
1) By Next-Generation Sequencing: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, Ribonucleic Acid Sequencing
2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Digital Polymerase Chain Reaction
3) By Microarray: Deoxyribonucleic Acid Microarray, Ribonucleic Acid Microarray, Protein Microarray
4) By Software And Services: Data Analysis And Interpretation Software, Genomic Data Management Tools, Custom Services, Cloud-Based Platforms And Reporting Tools
Neurogenomics Market Trends Driving Strategic Industry Expansion
Leading entities within the neurogenomics sector are concentrating their efforts on pioneering sophisticated solutions, including comprehensive whole genome sequencing platforms, aimed at improving both the identification and comprehension of intricate neurological conditions. These whole genome sequencing platforms serve as vital instruments for examining an individual’s entire DNA blueprint, thereby facilitating the pinpointing of genetic predispositions associated with neurological ailments. As an illustration, in April of 2023, Centogene N.V., a biotechnology firm headquartered in Germany specializing in the diagnosis and investigation of uncommon diseases, introduced CentoGenome, recognized as the globe’s most exhaustive whole-genome sequencing (WGS) offering designed for the diagnosis of rare and neurodegenerative disorders. This particular platform leverages PCR-free technology to deliver high-fidelity, impartial sequencing data, even across challenging genomic segments. It incorporates an advanced bioinformatics pipeline and expert analysis to boost the accuracy of variant detection, thereby identifying virtually all pathogenic variants through a singular diagnostic process. Furthermore, it features a unified, ongoing diagnostic support system, which includes complimentary reclassification of detected variants and subsequent confirmatory testing as new scientific discoveries emerge over time.
Neurogenomics Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc, PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., BGI Genomics Co. Ltd., GenScript Biotech Corporation, Roche Diagnostics GmbH, Illumina Cambridge Ltd.
Access The Complete Neurogenomics Market Report:
https://www.thebusinessresearchcompany.com/report/neurogenomics-global-market-report
Neurogenomics Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the neurogenomics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model